BAMF
CYTK icon

BI Asset Management Fondsmaeglerselskab’s Cytokinetics CYTK Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,145
Closed -$779K – 759
2023
Q1 		$779K Buy
22,145
+19,896
+885% +$812K 0.02% 383
2022
Q4 		$103K Buy
+2,249
New +$96.8K ﹤0.01% 604

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's CYTK Position: Q2 2023 in Review

BI Asset Management Fondsmaeglerselskab sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 22,145 shares — an estimated $779K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in CYTK in Q4 2022 and held it in 2 quarters. The position peaked at $779K in Q1 2023. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 22,145 Cytokinetics shares in Q2 2023, an estimated $779K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Cytokinetics in Q4 2022 and held it in 2 quarters.
  • BI Asset Management Fondsmaeglerselskab's Cytokinetics position peaked at $779K in Q1 2023.
  • 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2023, filed 3 Aug 2023.